Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125(21):3714–28.

Article  PubMed  PubMed Central  Google Scholar 

Pfizer, Arvinas. VEPPANU (vepdegestrant) tablets, for oral use: US prescribing information. 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219835. Accessed 21 Jul 2026.

Arvinas. Arvinas announces FDA approval of VEPPANU (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer [media release]. 2026. https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-fda-approval-veppanu-vepdegestrant-treatment. Accessed 21 Jul 2026.

Arvinas. Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC(Rm) ER degrader being developed in ER+/HER2- Breast Cancer [media release]. 2023. https://ir.arvinas.com/news-releases/news-release-details/arvinas-and-pfizer-awarded-innovation-passport-designation-uk. Accessed 21 Jul 2026.

Pfizer. Pfizer Pipeline. 2026. https://www.pfizer.com/science/drug-product-pipeline. Accessed 2 Jul 2026.

Rigel. Rigel enters exclusive global licensing agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the treatment of 2L+ ER+/HER2-, ESR1m advanced or metastatic breast cancer [media release]. 2026. https://www.rigel.com/news-media/press-releases/detail/437/rigel-enters-exclusive-global-licensing-agreement-for. Accessed 21 Jul 2026.

Rigel. Rigel announces closing of licensing agreement for VEPPANU™ (vepdegestrant) [media release]. 2026. https://www.rigel.com/news-media/press-releases/detail/441/rigel-announces-closing-of-licensing-agreement-for. Accessed 21 Jul 2026.

Carrick Therapeutics. Carrick therapeutics announces clinical trial collaboration with Arvinas and Pfizer to evaluate samuraciclib and vepdegestrant combination [media release]. 2023. https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/19/carrick-therapeutics-announces-clinical-trial-collaboration. Accessed 21 Jul 2026.

Arvinas, Pfizer. Arvinas and Pfizer announce global collaboration to develop and commercialize PROTAC(Rm) protein degrader ARV-471 [media release]. 2021. https://ir.arvinas.com/static-files/b1919793-f589-4c17-8645-373328842b1e. Accessed 21 Jul 2026.

Arvinas. 2019 Annual Report. 2019. https://ir.arvinas.com/static-files/555a5c8e-63d0-47f2-835c-b614fd8e66da. Accessed 23 Jun 2026.

Gough SM, Flanagan JJ, Teh J, et al. Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clin Cancer Res. 2024;30(16):3549–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campone M, De Laurentiis M, Jhaveri K, et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 2025;393(6):556–68.

Article  CAS  PubMed  Google Scholar 

Tran L, Winton JA, Matschke KT, et al. The effect of itraconazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adult participants. Clin Ther. 2026;48(2):179–85.

Article  CAS  PubMed  Google Scholar 

Wang H, Winton JA, Matschke KT, et al. Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults. Br J Clin Pharmacol. 2026;92(7):2183–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tran L, Chen N, Winton JA, et al. Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants. Br J Clin Pharmacol. 2026. https://doi.org/10.1002/bcp.70636.

Article  PubMed  Google Scholar 

Yang DZ, Zhou L, Winton JA, et al. Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants. Br J Clin Pharmacol. 2025;91(12):3501–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campone M, De Laurentiis M, Hu X, et al. Patient-reported outcomes (PROs) with vepdegestrant (VEP) vs fulvestrant (FUL) in patients (pts) with estrogen receptor (ER) 1 gene mutated (ESR1m) ER+/human epidermal growth factor receptor 2 (HER2) : advanced breast cancer (aBC) in the phase 3 VERITAC-2 trial [abstract and presentation no. 489MO]. Ann Oncol. 2025;36(Suppl 2):S380–S1.

Hamilton EP, Hurvitz SA, McAndrew NP, et al. Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: updated phase Ib cohort results [abstract plus poster no. 218P]. ESMO Open. 2024;9(Suppl 4):103240.

Layman RM, Jerzak KJ, Hilton JF, et al. Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus abemaciclib (ABE) in ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): TACTIVE-U phase 1b/2 results [abstract no. 1067]. J Clin Oncol. 2026. https://doi.org/10.1200/JCO.2026.44.16_suppl.106.

Telli ML, Ruiz-Borrego M, Yonemori K, et al. Vepdegestrant, a proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus atirmociclib (ATI) in ER+/HER2- advanced breast cancer (ABC): TACTIVE-K phase 1b/2 results [abstract no. 1075]. J Clin Oncol. 2026. https://doi.org/10.1200/JCO.2026.44.16_suppl.1075.

Fasching PA, Bermejo B, Arkania E, et al. TACTIVE-N: Phase 2 study of neoadjuvant vepdegestrant, a PROteolysis TArgeting chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal ER plus /human epidermal growth factor receptor 2 (HER2)-localized breast cancer (BC) [abstract plus presentation no. 293MO]. Ann Oncol. 2025;36(Suppl 2):S304-S5.

Chien J, Mukhtar RM, Yau C, et al. I-SPY2 Endocrine Optimization Pilot (EOP): neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients with stage 2/3 HR+HER2-negative breast cancer (BC). Clin Cancer Res. 2026;32(4 Suppl):PD10-02.

Guardant Health. Guardant health receives FDA approval for Guardant360 CDx as a companion diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for patients with ER+/HER2- advanced breast cancer with ESR1 mutations [media release]. 2026. https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-a-Companion-Diagnostic-for-Arvinas-and-Pfizers-VEPPANU-vepdegestrant-for-Patients-with-ERHER2--Advanced-Breast-Cancer-with-ESR1-Mutations/default.aspx. Accessed 21 Jul 2026.

Guardant Health. Guardant360® CDx technical information. 2025. https://www.guardantcomplete.com/assets/pdf/Guardant360-CDx-Technical-Information-US.pdf. Accessed 21 Jul 2026.